In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

RegeneRx Biopharmaceuticals, Inc.

http://www.regenerx.com

Latest From RegeneRx Biopharmaceuticals, Inc.

Abbott And Coroventis Partner To Address Often-Overlooked Microvascular Dysfunction

Coroventis’ CoroFlow software allows Abbott’s PressureWire X to diagnose coronary microvascular dysfunction caused by invisible blockages in the heart’s smallest arteries.

Deals Diagnostics

What’s Next? Five Things To Look Out For In August

Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.

Sales & Earnings Generic Drugs

Updated: Multiple Biosimilars To Avastin Have Launched In EU

Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.

BioPharmaceutical Cancer

FDA Schedules Advisory Panel To Review Neovasc’s Angina Treatment

The US FDA's Circulatory System Devices Panel will meet on 27 October to evaluate Neovasc’s Reducer device, a minimally invasive treatment for drug-refractory angina.

Advisory Committees Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register